Physician profile
Lisa Hazard
NPI 1477633386
$913.86
in general payments reported to CMS, 2019-2025
11 companies · $37.62 in 2025
The $37.62 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.47 · 2020: $54.14 · 2021: $250 · 2022: $140 · 2023: $50.31 · 2024: $294 · 2025: $37.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $188.82 | 2021-2024 | Tagrisso |
| Janssen Biotech, INC. | $129.58 | 2024 | Rybrevant, Tecvayli, Talvey |
| Amgen INC. | $128.14 | 2019-2021 | |
| Myovant Sciences INC. | $102.71 | 2021-2022 | |
| Viewray Technologies INC | $92.25 | 2022 | |
| Merck Sharp & Dohme LLC | $80.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $78.08 | 2024-2025 | |
| Elekta, INC. | $50.31 | 2023 | Elekta Unity |
| Bayer Healthcare Pharmaceuticals INC. | $33.37 | 2019-2020 | |
| Eusa Pharma (US) LLC | $15.20 | 2022 | |
| Lilly USA, LLC | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hazard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.